unpaired 2-tailed student’s ttest and 1-way anova followed by newman–keuls multiple comparison test  (GraphPad Software Inc)

Journal: Translational Oncology

Article Title: BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy

doi: 10.1016/j.tranon.2020.100897

Figure Lengend Snippet: In vivo activities of BPRDP056 against tumor growths in mice. BPRDP056 is active in a broad spectrum against human colorectal COLO 205 (A), pancreatic MIA PaCa-2 (B), prostate PC-3 (C), hepatocellular Hep G2 (D) and glioblastoma U-87 MG (E) tumor growths in male nude mice and breast MDA-MB-231 (F) tumor growths in female SCID mice. BPRDP056 of 10 and 20 mg/kg and SN38 of 10 mg/kg at once daily for 5 consecutive days a week for 2 consecutive weeks with an interval of 2 non-dosing days (days 1–5 + days 8–12); BPRDP056 of 40 mg/kg, BPRDP067 of 40 mg/kg, CPT-11 of 40 mg/kg, and BPRDP060 of 33 mg/kg at twice (day 1 and day 4) a week for 2 weeks; paclitaxel of 20 mg/kg at once (day 1) a week for 2 weeks; sorafenib of 30 mg/kg orally gavaged daily in days 1–5 + days 8–12; temozolomide of 50 mg/kg orally gavaged daily for 5 consecutive days. Data are expressed as the mean ± SEM. *: p < 0.05, treated vs. vehicle control by ANOVA followed by using the Student-Newman-Keuls test. Arrows indicate the timepoints of the dosing.

Article Snippet: Statistical differences between the tumor volumes of the vehicle-treated control and compound-treated groups were determined by using ANOVA and followed by Student-Newman-Keuls multiple comparison test (GraphPad Prism, San Diego, CA, USA).

Techniques: In Vivo, Control